Strong Genetic

Gaucher Disease

Name: Gaucher Disease
Creator: Realised
Published: 2026-03-01

GeneGBA1rsIDrs76763715, rs421016, rs80356769InheritanceAutosomal recessiveCarrier frequency~1 in 15 Ashkenazi Jewish; ~1 in 100 general populationSystemCarrier Screening

Summary

Gaucher disease is a lysosomal storage disorder where the enzyme glucocerebrosidase is deficient, causing fatty substances to accumulate in the spleen, liver, bone marrow, and sometimes the brain. Type 1 (non-neuronopathic) is the most common form, especially in Ashkenazi Jewish populations, and causes enlarged spleen and liver, bone pain and fractures, fatigue, and low blood counts. Crucially, Type 1 is treatable with enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Types 2 and 3 involve the nervous system and are more severe — Type 2 is typically fatal in infancy, while Type 3 progresses more slowly with neurological involvement.

Practical takeaway

This matters when you are planning children. If you carry a GBA1 variant, your partner should be tested before or early in pregnancy. Partner testing is available through a GP referral to clinical genetics or through expanded carrier screening panels. The specific variants matter — N370S/N409S is associated almost exclusively with Type 1 (treatable), while L444P/L483P is more commonly associated with Types 2/3 (neuronopathic). A genetic counsellor can interpret the specific variant combination and discuss what it means for potential offspring. Realised flags the need for this conversation but does not replace it.

Evidence detail

What Carrier Status Means For You

You are not affected by Gaucher disease. You carry one working copy and one non-working copy of the GBA1 gene. Your children could be affected only if your partner also carries a pathogenic GBA1 variant — in that case, each pregnancy carries a 25% chance of the child being affected, a 50% chance of being a carrier, and a 25% chance of inheriting no variants. Because Type 1 Gaucher disease is treatable, early identification in affected children allows prompt treatment that prevents most complications.

Important — carrier status health implications: GBA1 is unusual among carrier conditions because carrier status itself has health relevance beyond reproduction. Heterozygous carriers of GBA1 pathogenic variants have approximately 5 times the population risk of developing Parkinson's disease. This does not mean you will develop Parkinson's — the absolute lifetime risk for carriers is estimated at 7-10%, compared to ~1-2% in the general population. Most carriers never develop Parkinson's disease. But this association is well-established and is the strongest known single-gene risk factor for PD. Realised surfaces this finding in the context of your overall neurological health profile, not as a prediction.

Population Context

Gaucher disease carrier frequency is highest in Ashkenazi Jewish populations (~1 in 15), making it the most common genetic condition in this group. The general population carrier rate is approximately 1 in 100. The N370S variant accounts for roughly 70% of pathogenic alleles in Ashkenazi Jewish carriers, which partly explains why Type 1 (the treatable form) predominates in this population. In non-Ashkenazi populations, the variant spectrum is broader and neuronopathic forms are proportionally more common. These patterns reflect ancestral population history, not individual destiny.

Limitations

23andMe tests 3 of the over 300 known pathogenic GBA1 variants. These 3 capture the most clinically significant mutations but miss rarer variants. A "not detected" result does not mean zero carrier risk. The variant tested matters for clinical interpretation — N370S is associated with milder Type 1 disease, while L444P is associated with neuronopathic forms, but genotype-phenotype correlation is imperfect and other genetic and environmental modifiers play a role. Clinical sequencing of the full GBA1 gene provides more comprehensive coverage. Note that GBA1 has a highly homologous pseudogene (GBAP1) that complicates sequencing — clinical labs use specialised methods to avoid false results from pseudogene reads.

Sources (6)

Open in the Library: search, filter, every entry →